Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Interferon beta 1a inhalation - Synairgen

Drug Profile

Interferon beta 1a inhalation - Synairgen

Alternative Names: AZD-9412; SNG-001

Latest Information Update: 26 Jun 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator University of Southampton
  • Developer Synairgen
  • Class Antineoplastics; Interferons
  • Mechanism of Action Immunostimulants; Interferon beta stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase II Chronic obstructive pulmonary disease
  • No development reported Influenza virus infections
  • Discontinued Asthma

Most Recent Events

  • 07 Feb 2018 Synairgen initiates a phase II trial for Chronic obstructive pulmonary disease (COPD) in United Kingdom (Inhalation)
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Influenza-virus-infections in United Kingdom (Inhalation, Aerosol)
  • 27 Sep 2017 Synairgen plans a clinical trial for Chronic obstructive pulmonary disease in winter of 2017/2018, for which regulatory application is being submitted
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top